Sign in

CARLISLE COMPANIES (CSL)

Earnings summaries and quarterly performance for CARLISLE COMPANIES.

Recent press releases and 8-K filings for CSL.

Carlisle Reports Q3 2025 Results and Updates Full-Year Guidance
CSL
Earnings
Guidance Update
Share Buyback
  • Carlisle (CSL) reported Q3 2025 revenue of $1.3 billion, an increase of 1% year-over-year, and adjusted EPS of $5.61.
  • The company revised its full-year 2025 guidance to anticipate flat revenue year-over-year and an adjusted EBITDA margin decline of approximately 250 basis points.
  • Performance was driven by the strength of the underlying CCM business, particularly strong reroofing demand, which was partially offset by ongoing challenges in residential and non-residential new construction markets.
  • Carlisle maintained its commitment to capital deployment, repurchasing 800,000 shares for $300 million in Q3, raising its dividend by 10%, and increasing its full-year share buyback target to $1.3 billion.
  • The company also issued $1 billion of debt in Q3, maintaining a net debt to EBITDA ratio of 1.4 times as of September 30, 2025.
Oct 29, 2025, 9:00 PM
Carlisle Companies Announces Q3 2025 Results and Revised Full-Year Outlook
CSL
Earnings
Guidance Update
Share Buyback
Demand Weakening
  • CSL reported Q3 2025 revenue of $1,347 million, a 1% year-over-year increase, with Adjusted EPS of $5.61 and an Adjusted EBITDA Margin of 25.9%.
  • The company returned $347 million to shareholders in Q3 2025 through dividends and share repurchases, and increased its share buyback target for the year to $1.3 billion.
  • CSL revised its full-year 2025 outlook to project flat revenue year-over-year and an Adjusted EBITDA margin compression of 250 basis points from 2024.
  • Performance was influenced by M&A contributions and strong commercial re-roofing, which helped to offset lower volumes from soft new construction and residential R&R markets.
Oct 29, 2025, 9:00 PM
Carlisle Companies Incorporated Announces Q3 2025 Results and Updates Full-Year Guidance
CSL
Earnings
Guidance Update
Share Buyback
  • Carlisle Companies Incorporated reported Q3 2025 revenue of $1.3 billion, a 1% year-over-year increase, though organic revenue declined 2%.
  • Adjusted EPS was $5.61, down 3% from the prior year, with an adjusted EBITDA margin of 25.9%, a 170 basis point decrease.
  • The company revised its full-year 2025 guidance, now expecting consolidated revenue to be flat year-over-year and adjusted EBITDA margin to decline approximately 250 basis points.
  • Carlisle increased its full-year 2025 share buyback target to $1.3 billion and announced a 10% dividend increase, its 49th consecutive annual increase.
Oct 29, 2025, 9:00 PM
Carlisle Companies Reports Q3 2025 Earnings
CSL
Earnings
Guidance Update
Share Buyback
  • Carlisle Companies reported Q3 2025 revenue of $1.3 billion, a 1% year-over-year increase, and adjusted EPS of $5.61, a 3% decrease.
  • The Carlisle Construction Materials (CCM) segment showed resilience with strong reroofing demand, maintaining an adjusted EBITDA margin of over 30%, while the Carlisle Weatherproofing Technologies (CWT) segment continued to be negatively impacted by soft new construction and residential markets.
  • The company repurchased 800,000 shares for $300 million in Q3 2025, raised its dividend by 10%, and increased its full-year 2025 share buyback target to $1.3 billion.
  • Carlisle updated its full-year 2025 outlook, expecting consolidated revenue to be flat year-over-year and adjusted EBITDA margins to decline approximately 250 basis points compared to 2024.
Oct 29, 2025, 9:00 PM
CSL Vifor and Travere Therapeutics Acknowledge Updated KDIGO Guidelines for IgA Nephropathy
CSL
  • CSL Vifor and Travere Therapeutics support the recently published KDIGO 2025 clinical practice guidelines for IgA Nephropathy (IgAN), which define diagnostic criteria, treatment goals, and treatment approaches for the disease.
  • The updated guidelines suggest treatment with FILSPARI® (sparsentan), a Dual Endothelin Angiotensin Receptor Antagonist (DEARA), as a potential first-line approach for IgAN-induced nephron loss, noting its proven efficacy compared to optimized RASi in clinical trials.
  • The PROTECT Study, a Phase 3 trial, showed that FILSPARI achieved a 49.8% mean reduction in proteinuria from baseline after 36 weeks, significantly outperforming the 15.1% reduction seen in irbesartan-treated patients.
  • FILSPARI is a non-immunosuppressive therapy approved in the U.S. and Europe, and has been launched in Germany, Austria, Switzerland, Luxembourg, and the UK.
Sep 26, 2025, 6:30 AM